Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: Predictive importance of induced early hypertension

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Schuster, Cornelia ^a,b   Eikesdal, Hans P ^a   Puntervoll, Hanne ^a,b   Geisler, Jürgen ^c,d   Geisler, Stephanie ^a   Heinrich, Daniel ^c,d   Molven, Anders ^a,b   Lønning, Per E ^a   Akslen, Lars A ^a,b   Straume, Oddbjørn ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DACARBAZINE; LACTATE DEHYDROGENASE; VASCULOTROPIN;

ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; BLEEDING; BRAF GENE; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTENSION; INDUCED EARLY HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE N RAS; OVARY METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 84862502742     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038364     Document Type: Article

References (41)

1. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116.
3. Busch C, Geisler J, Lillehaug JR, Lonning PE, (2010) MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 46: 2127-2133.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
6. Streit M, Detmar M, (2003) Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22: 3172-3179.
7. Straume O, Akslen LA, (2003) Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 6: 295-301.
8. Straume O, Salvesen HB, Akslen LA, (1999) Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol 15: 595-599.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
11. Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, et al. (2011) A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 34: 509-515.
12. Vihinen PP, Hernberg M, Vuoristo MS, Tyynela K, Laukka M, et al. (2010) A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 20: 318-325.
13. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, et al. (2010) Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 16: 5862-5872.
14. Corrie PG, Basu B, Zaki KA, (2010) Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol 2: 367-380.
15. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, et al. (2011) BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. J Clin Oncol.
16. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434.
17. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
18. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
20. Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, et al. (2011) Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 29: 2582-2589.
21. Ratain MJ, Eckhardt SG, (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22: 4442-4445.
22. Suman VJ, Dueck A, Sargent DJ, (2008) Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest 26: 439-444.
23. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181.
24. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
25. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J, (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
26. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, et al. (2008) Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18: 29-35.
27. Simon R, Thall PF, Ellenberg SS, (1994) New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med 13: 417-429.
28. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, et al. (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14: 2367-2376.
29. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, et al. (2011) Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clin Cancer Res.
30. Jubb AM, Harris AL, (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11: 1172-1183.
31. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, et al. (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763-773.
32. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM, (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54: 652-658.
33. Neagoe PE, Lemieux C, Sirois MG, (2005) Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and-2 heterodimer. J Biol Chem 280: 9904-9912.
34. Ferrara N, Alitalo K, (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364.
35. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, et al. (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9: 4514-4521.
36. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, et al. (2010) Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 128: 2306-2316.
37. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K, (2011) Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29: 2635-2644.
38. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, et al. (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29: 2645-2652.
39. Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, et al. (2011) Beta Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev.
40. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, et al. (2011) Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171: 779-781.
41. Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, et al. (2011) Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin Cancer Res 17: 1200-1209.